Diagnosis and therapy of tacrolimus toxicity in a liver transplant recipient during COVID-19 treatment
Feng Zhu a , b , # , Yi-Ming Wang a , # , Ming Ni a , # , Yuan Liang a , Jie-Hui Huang b , Xue-Hao Wang a , Feng Cheng a , Ling Lu a , c , ∗
a Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Liver Transplantation, Chinese Academy of Medical
Sciences, NHC Key Laboratory of Liver Transplantation, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical
Sciences, Nanjing 210000, China
b Department of Respiratory and Critical Care Medicine, Wuxi Fifth People’s Hospital, Wuxi 214000, China
c Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing
Medical University, Nanjing 210000, China
∗ Corresponding author at: Hepatobiliary Center, The First Affiliated Hospital of
Nanjing Medical University, Nanjing 210 0 0 0, China
E-mail address: lvling@njmu.edu.cn (L. Lu) .
# Contributed equally.
Abstract：SARS-CoV-2, the pathogen responsible for the pandemic of coronavirus disease 2019 (COVID-19), has had profound impacts on human health, and its antagonist Paxlovid is a commonly used treatment option [1]. However, treatment selection for immunosuppressed patients, such as liver recipients, remains uncertain due to potential drug interactions and the risk of immunosuppressant dosage adjustment, which can cause liver injury [2]. Therefore, we retrospectively analyzed a case of liver recipient with COVID-19 who experienced deteriorating liver function during anti-COVID-19 therapy.
引用本文:
. [J]. Hepatobiliary Pancreat Dis Int, 2024, 23(3): 326-330.
Zhu F, Wang YM, Ni M, Liang Y, Huang JH, Wang XH, Cheng F, Lu L. Diagnosis and therapy of tacrolimus toxicity in a liver transplant recipient during COVID-19 treatment. Hepatobiliary Pancreat Dis Int, 2024, 23(3): 326-330.
2024, Vol. 23 
